Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0.0298850574712643 0.0160919540229884
Stock impact report

Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia i...

Akebia Therapeutics, Inc. (AKBA) 
Last akebia therapeutics, inc. earnings: 3/10 07:49 am Check Earnings Report
US:NASDAQ Investor Relations: ir.akebia.com/investor-relations
Company Research Source: Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco, Inc. (JT) and its subsidiary Torii Pharmaceutical Co., Ltd. (Torii), reported positive top-line results from a pivotal Phase 3 comparative study evaluating Riona® Tablets 250mg (generic name in Japan: ferric citrate hydrate) for the treatment of iron deficiency anemia (IDA) in adult patients in Japan. JT and Torii hold the exclusive rights to develop and commercialize Riona in Japan. Upon successful completion of its Phase 3 program, JT and Torii stated that they expect to file an application for approval of IDA as an additional indication for Riona in Japan.Riona was approved in Japan in 2014 as an oral treatment for the improvement of hyperphosphatemia in patients with chronic kidney disease (CKD), including dialysis-dependent and non-dialysis dependent CKD. Ferric citrate is approved and marketed in the United States by Akebia under the tra Show less Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for AKBA alerts
Opt-in for
AKBA alerts

from News Quantified
Opt-in for
AKBA alerts

from News Quantified